Functional gastrointestinal disorders in women with systemic lupus erythematosus: A case‐control study

Background Systemic lupus erythematosus (SLE) is an autoimmune disease with multisystemic involvement. Gastrointestinal (GI) manifestations are frequent but functional gastrointestinal disorders (FGIDs) have scarcely been studied in SLE. To determine the prevalence of FGIDs and their potential risk...

Full description

Saved in:
Bibliographic Details
Published inNeurogastroenterology and motility Vol. 31; no. 11; pp. e13693 - n/a
Main Authors García‐Carrasco, Mario, Mendoza‐Pinto, Claudia, Munguía‐Realpozo, Pamela, Méndez‐Valderrabano, Fabiola, Méndez Martínez, Socorro, Etchegaray Morales, Ivet, Montiel‐Jarquín, Álvaro, López‐Colombo, Aurelio, Schmulson, Max
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.11.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Systemic lupus erythematosus (SLE) is an autoimmune disease with multisystemic involvement. Gastrointestinal (GI) manifestations are frequent but functional gastrointestinal disorders (FGIDs) have scarcely been studied in SLE. To determine the prevalence of FGIDs and their potential risk factors in SLE female patients vs controls. Methods Systemic lupus erythematosus patients meeting the American College of Rheumatology (ACR) criteria and controls completed the Rome III questionnaire for FGIDs and a structured interview to assess sociodemographic, clinical, and treatment variables after excluding organic GI diseases. Logistic regression was used to determine risk factors (ie, alcohol drinking, medications) for FGIDs. Key Results Responders included 113 SLE patients and 122 age‐matched controls. The presence of at least one FGIDs was higher in SLE (73.4%) vs controls (54.1%), P = .003. The most frequent FGIDs in SLE patients were nausea and vomiting disorders (NVD), belching disorders, globus, anorectal pain, functional heartburn (FH), and functional bloating (FB). After adjustment for confounding variables, SLE was associated with NVD (OR: 7.1, 95% CI: 2.7‐19.1) globus (3.5, 1.3‐9.3), anorectal pain (3.4, 1.4‐8.4), and FH (2.5, 1.5‐4.4). The simultaneous presence of >1 FGID was more common in SLE patients than controls (69.8% vs 31.8%). Glucocorticoids (5.2, 1.3‐19.9) and non‐steroidal anti‐inflammatory drugs (NSAIDs; 3.0, 1.1‐8.0) were associated with any FGID in SLE patients while alcohol drinking with gallbladder/sphincter of Oddi disorders 7.4 (1.1‐47.3). Conclusions and Inferences Functional gastrointestinal disorders are more frequent in SLE patients compared with controls. Medication that may alter gastrointestinal homeostasis, such as glucocorticoids and NSAIDs, are potential risk factors for FGIDs in SLE. In this cross‐sectional, observational study including 113 systemic lupus patients (SLE) patients and 112 age‐matched controls, Functional gastrointestinal disorders (FGIDs) were more frequent in SLE patients compared with controls. Medication that may alter gastrointestinal homeostasis, such as glucocorticoids and NSAIDs are potential risk factors for FGIDs in SLE.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1350-1925
1365-2982
DOI:10.1111/nmo.13693